Ledipasvir

Ledipasvir is an inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A). It inhibits viral replication in genotype 1a and 1b HCV replicon cells (EC50s = 0.031 and 0.004 nM, respectively). It also inhibits viral replication in genotype 2a, 2b, 3a, 4a, 4d, 5a, 6a, and 6e HCV replicon cells (EC50s = 0.11-530 nM). Lepidasvir acts synergistically with IFN-alpha, ribavirin (Cay-16757), or GS-9669 and additively with GS-9451, simeprevir (Cay-22144), daclatasvir (Cay-23730), or sofosbuvir (Cay-15402) to inhibit viral replication in genotype 1a HCV replicon cells. Formulations containing ledipasvir have been used in combination therapy for the treatment of chronic HCV infection.Formal Name: N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid, methyl ester. CAS Number: 1256388-51-8. Synonyms: GS-5885. Molecular Formula: C49H54F2N8O6. Formula Weight: 889.0. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 20 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS (pH 7.2)(1:2): 0.33 mg/ml. lambdamax: 219, 334 nm. SMILES: FC1(F)C2=C(C=CC(C3=CC(NC([C@H]4N(C([C@H](C(C)C)NC(OC)=O)=O)[C@@H]5CC[C@H]4C5)=N6)=C6C=C3)=C2)C7=CC=C(C8=CN=C([C@@H]9CC%10(CC%10)CN9C([C@H](C(C)C)NC(OC)=O)=O)N8)C=C71. InChi Code: InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14. InChi Key: VRTWBAAJJOHBQU-KMWAZVGDSA-N.